Literature DB >> 28128336

Prophylactic Ketamine Attenuates Learned Fear.

Josephine C McGowan1,2, Christina T LaGamma2,3, Sean C Lim3, Melina Tsitsiklis1, Yuval Neria4,5, Rebecca A Brachman4, Christine A Denny3,4.   

Abstract

Ketamine has been reported to be an efficacious antidepressant for major depressive disorder and posttraumatic stress disorder. Most recently, ketamine has also been shown to be prophylactic against stress-induced depressive-like behavior in mice. It remains unknown, however, when ketamine should be administered relative to a stressor in order to maximize its antidepressant and/or prophylactic effects. Moreover, it is unknown whether ketamine can be prophylactic against subsequent stressors. We systematically administered ketamine at different time points relative to a fear experience, in order to determine when ketamine is most effective at reducing fear expression or preventing fear reactivation. Using a contextual fear conditioning (CFC) paradigm, mice were administered a single dose of saline or ketamine (30 mg/kg) at varying time points before or after CFC. Mice administered prophylactic ketamine 1 week, but not 1 month or 1 h before CFC, exhibited reduced freezing behavior when compared with mice administered saline. In contrast, ketamine administration following CFC or during extinction did not alter subsequent fear expression. However, ketamine administered before reinstatement increased the number of rearing bouts in an open field, possibly suggesting an increase in attentiveness. These data indicate that ketamine can buffer a fear response when given a week before as prophylactic, but not when given immediately before or after a stress-inducing episode. Thus, ketamine may be most useful in the clinic if administered in a prophylactic manner 1 week before a stressor, in order to protect against heightened fear responses to aversive stimuli.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28128336      PMCID: PMC5518899          DOI: 10.1038/npp.2017.19

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  72 in total

Review 1.  Rearing on hind legs, environmental novelty, and the hippocampal formation.

Authors:  Colin Lever; Stephen Burton; John O'Keefe
Journal:  Rev Neurosci       Date:  2006       Impact factor: 4.353

2.  Consequences of extinction training on associative and non-associative fear in a mouse model of Posttraumatic Stress Disorder (PTSD).

Authors:  Yulia Golub; Christoph P Mauch; Maik Dahlhoff; Carsten T Wotjak
Journal:  Behav Brain Res       Date:  2009-08-22       Impact factor: 3.332

3.  Eye movement desensitization: a new treatment for post-traumatic stress disorder.

Authors:  F Shapiro
Journal:  J Behav Ther Exp Psychiatry       Date:  1989-09

4.  Acquisition of contextual Pavlovian fear conditioning is blocked by application of an NMDA receptor antagonist D,L-2-amino-5-phosphonovaleric acid to the basolateral amygdala.

Authors:  M S Fanselow; J J Kim
Journal:  Behav Neurosci       Date:  1994-02       Impact factor: 1.912

5.  Early post-stressor intervention with propranolol is ineffective in preventing posttraumatic stress responses in an animal model for PTSD.

Authors:  Hagit Cohen; Zeev Kaplan; Ori Koresh; Michael A Matar; Amir B Geva; Joseph Zohar
Journal:  Eur Neuropsychopharmacol       Date:  2010-12-30       Impact factor: 4.600

6.  An Abrupt Transformation of Phobic Behavior After a Post-Retrieval Amnesic Agent.

Authors:  Marieke Soeter; Merel Kindt
Journal:  Biol Psychiatry       Date:  2015-04-14       Impact factor: 13.382

7.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Authors:  Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

8.  Effects of ketamine on nociception and gastrointestinal motility in mice are unaffected by naloxone.

Authors:  R N Takahashi; G S Morato; G A Rae
Journal:  Gen Pharmacol       Date:  1987

9.  From Mice to Men: Can Ketamine Enhance Resilience to Stress?

Authors:  Rebecca B Price
Journal:  Biol Psychiatry       Date:  2016-02-15       Impact factor: 13.382

10.  The Primary Prevention of PTSD in Firefighters: Preliminary Results of an RCT with 12-Month Follow-Up.

Authors:  Petra M Skeffington; Clare S Rees; Trevor G Mazzucchelli; Robert T Kane
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

View more
  34 in total

1.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

2.  Ketamine Alleviates Fear Generalization Through GluN2B-BDNF Signaling in Mice.

Authors:  Muhammad Asim; Bo Hao; Yu-Han Yang; Bu-Fang Fan; Li Xue; Yan-Wei Shi; Xiao-Guang Wang; Hu Zhao
Journal:  Neurosci Bull       Date:  2019-08-23       Impact factor: 5.203

3.  Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Authors:  Jerome H Taylor; Angeli Landeros-Weisenberger; Catherine Coughlin; Jilian Mulqueen; Jessica A Johnson; Daniel Gabriel; Margot O Reed; Ewgeni Jakubovski; Michael H Bloch
Journal:  Neuropsychopharmacology       Date:  2017-08-29       Impact factor: 7.853

Review 4.  Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population.

Authors:  Charlene Faye; Josephine C Mcgowan; Christine A Denny; Denis J David
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

5.  Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress.

Authors:  Josephine C McGowan; Collin Hill; Alessia Mastrodonato; Christina T LaGamma; Alexander Kitayev; Rebecca A Brachman; Niven R Narain; Michael A Kiebish; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2018-03-29       Impact factor: 7.853

6.  Prophylactic efficacy of 5-HT4R agonists against stress.

Authors:  Briana K Chen; Indira Mendez-David; Victor M Luna; Charlène Faye; Alain M Gardier; Denis J David; Christine A Denny
Journal:  Neuropsychopharmacology       Date:  2019-10-10       Impact factor: 7.853

7.  Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.

Authors:  Oliver Vranjkovic; Garrett Winkler; Danny G Winder
Journal:  Neuropsychopharmacology       Date:  2018-05-24       Impact factor: 7.853

8.  Psychedelic Microdosing: Prevalence and Subjective Effects.

Authors:  Lindsay P Cameron; Angela Nazarian; David E Olson
Journal:  J Psychoactive Drugs       Date:  2020-01-23

9.  Ventral CA3 Activation Mediates Prophylactic Ketamine Efficacy Against Stress-Induced Depressive-like Behavior.

Authors:  Alessia Mastrodonato; Randy Martinez; Ina P Pavlova; Christina T LaGamma; Rebecca A Brachman; Alfred J Robison; Christine A Denny
Journal:  Biol Psychiatry       Date:  2018-02-23       Impact factor: 13.382

Review 10.  Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.

Authors:  Irina Esterlis; Sophie E Holmes; Priya Sharma; John H Krystal; Christine DeLorenzo
Journal:  Biol Psychiatry       Date:  2017-09-19       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.